Oral medicine has been developed by the Institute of Nuclear Medicine and Allied Sciences, Drdo Laboratory, in collaboration with the Laboratory of Dr. Reddy, Hyderabad. The results of the phase III clinical trial show that this molecule helps in faster recovery than patients treated in hospitals and reduces additional oxygen dependence.
The Nuclear Medical Institute and the Allies (INMAS) collaborated with the Laboratory of Dr. Reddy, Hyderabad, developed the anti-Covid-19 therapy application of 2-deoxy-d-glucose (2-DG) drugs. The third phase of the results of clinical trials has shown that this molecule helps in faster recovery than patients treated in hospitals and reduces additional oxygen dependence. The proportion of higher patients treated with 2-DG shows the negative conversion of RT-PCR in patients infected with Coronavirus.
Responding to the call of Prime Minister Narendra Modi for readiness to pandemic, Drdo took the initiative to develop an anti-covid 2-dg therapy application. In April 2020, when the first wave of Pandemic hit India, scientists in the laboratory, Inmas, conducted experiments with the help of Hyderabad-based centers for cellular and molecular biology (CCMB) and found that this molecule worked effectively against the SARS-COV-2 virus and inhibited Virus growth. Based on these results, general controlling drugs (DCGI) Standard Central Medicines (CDSCO) allowed 2-DG phase-II clinical trials in Covid-19 patients in May 2020.
DRDO along with Industrial Partners Dr. Reddy’s Laboratories began clinical trials to test the security and efficacy of drugs in Covid-19 patients.
“In the Phase-II trial (including the starting dose) was carried out between May and October 2020, the drug was found safe in Covid-19 patients, and showed a significant increase in their recovery. Phase iia was carried out in 6 hospitals and phase IIB (dosage Start) Clinical trials were carried out in 11 hospitals throughout the country. The Phase-II trial was conducted in 110 patients. In the trend of efficacy, patients treated with 2-DG showed simtomatic drugs that were faster than various endpoints (SOC) at various endpoints (SOC) at various endpoints (SOC) at various endpoints (SOC) at various endpoints. The trend that is significantly profitable (difference 2.5 days) is seen in terms of average time to achieve normalization of specific vital sign parameters if Compared to SOC, “said a Drdo Top official on Saturday.
The next official said that based on successful results, DCGI then allowed phase III of clinical trials in November 2020. conducted in 220 patients between December 2020 and March 2021 in 27 Covid-19 hospitals in West Bengal, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu.
“Detailed data from phase-III clinical trials presented in DCGI. In a 2-DG arm significantly higher the proportion of the patient increases in symptoms and becomes free of additional oxygen dependence (42% vs 31%) on day 3 compared to SOC, shows The initial assistance of oxygen / dependency therapy. Similar trends were observed in patients more than 65 years, “said DRDO official.
DCGI has 1 May granted permission for drug emergency use as additional therapy in medium covid-19 patients to severe. Become a generic molecule and glucose analog, can be easily produced and provided in many countries, Drdo said.
This drug comes in sachets in the form of powder taken orally by dissolving it in water. It accumulates in the cells infected with the virus and prevents the growth of the virus by stopping the synthesis of viruses and energy production. Selective accumulation of cells infected with viruses makes this medicine unique.
At the second wave of the Coronavirus Pandemy Palu Palu State and a large number of patients require severe oxygen dependence and hospitalization, the drug is expected to save valuable lives because of the mechanism of drug operations in infected cells. It also reduces the hospital stay of Covid-19 patients and burdens the state health infrastructure.